Table 1.
Baseline clinical and laboratory characteristics of 711 hospitalized HIV patients.
| Data | No. (%) |
|---|---|
| Age (years) <30 | 178 (25.0%) |
| 30–49 | 375 (52.7%) |
| ≥50 | 158 (22.2%) |
| Male | 659 (92.7%) |
| ART prior to admission | 308 (43.3%) |
| ART <6 m | 156 |
| ART >6 m without virological failure | 121 |
| ART >6 m with virological failure | 31 |
| The interval of fever (days) >7 | 456 (64.1%) |
| BMI <16 kg/m2 | 32 (4.5%) |
| Hepatitis B virus-coinfection | 73 (10.3%) |
| Hepatitis C virus-coinfection | 9 (1.3%) |
| Hyperlipidemia | 166 (23.3%) |
| Diabetes | 30 (4.2%) |
| Hypertension | 28 (3.9%) |
| The cigarette index >400 | 137 (19.3%) |
| Admission after 20160615 | 192 (27.0%) |
| The causes of hospital admission | |
| AIDS-related illnesses | 532 (74.8%) |
| Adverse drug event | 143 (20.1%) |
| Others | 36 (5.1%) |
| WHO clinical stage III–IV | 532 (74.8%) |
| Candidiasis | 358 (50.4%) |
| PJP | 350 (49.2%) |
| Respiratory failure | 142 |
| TB | 282 (39.7%) |
| Respiratory failure | 5 |
| Extra-pulmonary TB | 101 |
| CNS infection | 66 (9.3%) |
| Cryptococcosis meningitis or meningoencephalitis | 27 |
| HIV encephalopathy | 14 |
| Tuberculous meningitis | 12 |
| CMV meningitis | 7 |
| Toxoplasma gondii encephalitis | 2 |
| Varicella-zoster virus meningitis | 2 |
| Neurosyphilis | 2 |
| Invasive fungal infection | 42 (5.9%) |
| Cryptococcal infection | 32 |
| Talaromyces marneffei infection | 6 |
| Aspergillosis infection | 4 |
| Cytomegalovirus retinitis | 38 (5.3%) |
| Malignant tumor | 34 (4.8%) |
| Lymphoma | 15 |
| Kaposi's sarcoma | 9 |
| Others | 10 |
| Bacterial bloodstream infection | 29 (4.1%) |
| Non-typhoidal salmonella | 15 |
| Others | 14 |
| Disseminated Mycobacterium avium complex disease | 9 (1.3%) |
| Serum IgM antibody to Mycoplasma pneumoniae | 44 (6.2%) |
| Serum antibody to Legionella pneumophila | 2 (0.3%) |
| Available positive bacteria from sputum | 28 (3.9%) |
| Klebsiella pneumoniae | 16 |
| CD4 T counts <200 (/μL) | 606 (85.2%) |
| CRP (>10 mg/L) | 511 (71.9%) |
| Albumin (<30 g/L) | 304 (42.8%) |
| ALT (>50 × U/L) | 250 (35.2%) |
| Hyponatremia | 237 (33.3%) |
| HB (<9 g/L) | 87 (12.2%) |
| Thrombocytopenia | 57 (8.0%) |
| Scr (>104 μmol/L) | 13 (1.8%) |
ART, antiretroviral therapy; BMI, body mass index; PJP, pneumocystis jiroveci pneumonia; TB, tuberculosis; CNS, central nervous system; HIV, human immunodeficiency virus; CMV, cytomegalovirus; CRP, C-reactive protein; ALT, glutamic alanine transaminase; HB, hemoglobin; Scr, serum creatinine.